ViennaLab Diagnostics GmbH

Personalize therapy of non-small cell lung cancer (NSCLC) patients with acquired EGFR gene mutations.

Mutations in the epidermal growth factor receptor (EGFR) gene are predictive of the response to EGFR tyrosine kinase inhibitor (TKIs) therapies. The ViennaLab StripAssay® identifies 30 EGFR mutations relevant for non-small cell lung cancer (NSCLC) TKI therapies.




  • NSCLC comprises approximately 85% of all lung cancers. Tumor specimens from patients should be tested for the presence of EGFR mutations prior to TKI treatment.
  • Patients carrying EGFR mutations known as `activating mutations´ may benefit from first- or second- or third-generation TKIs. Patients carrying the `resistance mutation´ EGFR T790M may benefit from third-generation TKI.
  • The EGFR XL StripAssay® is designed to assist clinicians in the stratification of patients considered for TKI therapy.


ProductReg. Stat.REFUnit SizeIFUBrochure
EGFR XL StripAssay® CE/IVD5-63020 tests



We use Matomo to analyze the access to our website. We pass on information about your use of our website to our partners for analysis. Our partners may combine this information with other data that you have provided to them or that they have collected as part of your use of the services. I agree.

Deny Allow